Rubicon Research reported strong Q1 FY27 results with 51% YoY revenue growth to INR534 Cr and 65% EBITDA growth to INR131 Cr, driven by the Arinna acquisition and specialty products. The company acquired a US manufacturing facility for USD2.9M to enhance its supply chain.
Rubicon Research has issued a corrigendum to its Integrated Annual Report for FY2025-26, correcting minor typographical errors in the Management Discussion & Analysis and updating shareholding categories. The company's core strategy and the notice of the Annual General Meeting remain unchanged.
Rubicon Research Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The company emphasizes innovation in pharmaceuticals and exports 98.44% of its turnover. They are also focused on environmental initiatives including waste management and energy efficiency.
Rubicon Research has announced a board meeting. They are proposing a final dividend of Rs. 1.50 per share, subject to shareholder approval at the upcoming AGM.
Rubicon Research Limited has announced a board meeting on July 20, 2026, to approve the merger of its wholly-owned subsidiary, Kia Health Tech Private Limited, with itself. This amalgamation aims to streamline operations and leverage combined resources for growth.
